Orthocell Limited (ASX:OCC)

Market Cap	238.75M
Revenue (ttm)	7.55M +42.1%
Net Income	-8.57M
EPS	-0.04
Shares Out	271.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	410,481
Average Volume	548,332
Open	0.8800
Previous Close	0.8800
Day's Range	0.8800 - 0.9400
52-Week Range	0.8550 - 1.7900
Beta	-0.27
RSI	25.64
Earnings Date	Feb 19, 2026

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OCC

Financial Performance

In 2025, Orthocell's revenue was 7.55 million, an increase of 42.05% compared to the previous year's 5.32 million. Losses were -8.57 million, 19.3% more than in 2024.